Organization | Sheikh Zayed Medical College

Sheikh Zayed Medical College Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial

2014

NCT03090035

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Shaikh Zayed Hospital, Lahore | Shaikh Zayed Medical Complex, Pakistan | Shaikh Zayed Post-Graduate Medical Institute | Sheikh Zayed Federal Postgraduate Medical Institute | Sheikh Zayed Medical College | Sheikh Zayed Medical College/Hospital

Active Ingredients

Drugs in Phase 3 Trials (7)

bupivacaine (Exparel) (2 trials)

dexmedetomidine (precedex) (6 trials)

honey (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

ketamine (ketalar) (1 trial)

nigella sativa (3 trials)

tramadol (Ultram) (2 trials)

Drugs in Phase 2 Trials (5)

alprazolam (1 trial)

chlorhexidine (hibitane) (1 trial)

iodine (1 trial)

ivermectin (stromectol) (1 trial)

Drugs in Phase 1 Trials (2)

lidocaine (xylocaine) (2 trials)

midazolam (versed) (2 trials)

Drugs in Other Trials (2)

metformin (glucophage) (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Coronavirus Infections (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 17
# of Trial APIs: 16